Slide 1: EASL Data Presentation & AB-836 Clinical Update
NASDAQ: ABUS www.arbutusbio.com June 27, 2022 EASL Data Presentation & AB - 836 Clinical Update
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified as forward - looking statements fo
Slide 3: AB-729-001 Phase 1a/1b Clinical Trial Baseline Characteristics
AB - 729 - 001 Phase 1a/1b Clinical Trial HBeAg : HBV E antigen | TDF: tenofovir disoproxil fumarate Part 3: Multiple Ascending Dose in cHBV Patients (n=7/cohort) E: 60mg Q4W HBV DNA - F: 60mg Q8W HBV DNA - G: 90mg Q8W + TDF HBV DNA+ I: 90mg Q8W HBV DNA - J: 90mg Q12W HBV DNA - K: 90mg Q8W HBV DNA -
Slide 4: Robust HBsAg Declines Irrespective of Dose, Schedule, HBeAg or HBV DNA Status
Robust HBsAg Declines Irrespective of Dose, Dosing Schedule, HBeAg or HBV DNA Status Mean (SE) Baseline and Δ log10 HBsAg by Visit Note: Last dose Cohort E, Week 44; Cohorts F, I, G, K: Week 40; Cohort J: Week 36; Mean (SE) values presented only if N≥5; one subject in Cohort J chose not to extend
Slide 5: HBsAg and HBeAg Declines in HBeAg+ Subjects: Cohort K
HBsAg and HBeAg Declines in HBeAg + Subjects: Cohort K Change in HBsAg vs time Change in HBeAg vs time 5
Slide 6: Robust HBsAg Declines Persist After Stopping AB-729
Data presented at EASL 2022 6 Change in HBsAg vs time Robust HBsAg Declines Persist After Stopping AB - 729 26 of 34 patients had HBsAg < 100 IU/mL at some point during the study 1 patient in Cohort E (baseline HBsAg = 583.5 IU/mL) who qualified but declined to participate in NA discontinuation sero
Slide 7: AB-729-001: Safety Summary
AB - 729 - 001: Safety Summary Adverse events and laboratory abnormalities TEAE: treatment - emergent adverse event; SAE: serious adverse event; Grading criteria: Division of AIDS Table for Grading the Sev erity of Adult and Pediatric Adverse Events, V2.1 TEAE window was 12 weeks post - last dose of
Slide 8: AB-729 and NA-Therapy Discontinuation Baseline Characteristics
AB - 729 and NA - Therapy Discontinuation Baseline Characteristics Subject Disposition Baseline Characteristics NA stopping criteria ALT <2 × ULN, and Undetectable HBV DNA, and HBeAg negative, and HBsAg <100 IU/mL at two consecutive visits at least 24 weeks after the last dose of AB - 729 8
Slide 9: HBV Markers in NA-Therapy Discontinuation Cohort
HBV Markers in NA - Therapy Discontinuation Cohort HBV Parameter Pt. 46 Pt. 51 Pt. 52 Pt. 53 Pt. 61 HBsAg (IU/mL) Study Day 1 1392 6765 1888 2368 2021 Week 48/EOT 5 29.61 9.54 22.76 1.64 Last Visit prior to NA d/c 10.53 64.9 3.95 69.06 3.99 Last available post - NA d/c 41.22 150.1 10.97 138.9 4.58 H
Slide 10: HBsAg, HBV DNA and ALT in NA Discontinuation Cohort
HBsAg, HBV DNA and ALT in NA Discontinuation Cohort 0 50 100 150 200 H B s A g ( I U / m L ) , H B V D N A ( I U / m L ) 0 50 100 150 200 A L T ( U / L ) 0 2 4 6 8 10 12 14 16 18 20 22 24 Time (Weeks) ALTHBV DNAHBsAg Subject=46 0 50 100 150 200 H B s A g ( I U / m L ) , H B V D N A ( I U / m L ) 0 5
Slide 11: Conclusions NA Discontinuation Cohort
Conclusions NA Discontinuation Cohort 11 AB - 729 treatment for 48 weeks at varying doses and intervals led to continued HBsAg declines to <100 IU/mL in 16 of 32 (50%) subjects which were maintained for at least 24 weeks after the last dose of AB - 729 Eleven of these 16 subjects met protocol - defi
Slide 12: HBV-Specific T-Cell Activation Increases with AB-729 Treated cHBV+ Subjects
HBV - Specific T - Cell Activation Increases with AB - 729 - Treated in cHBV + Subjects 12 Upregulation of HBV - specific T cell activation markers observed in all 7 subjects assessed to date Two profiles of HBV - specific T cell IFN - γ responses observed Elevation between Wk 16 - 28 which coincide
Slide 13: Exhausted CD8+ T-Cells Decreased in 4/6 AB-729-Treated cHBV+ Subjects
Exhausted CD - 8+ T - Cells Decreased in 4/6 AB - 729 - Treated cHBV + subjects 13 B a s e l i n e T r e a t m e n t E n d ( W k 4 8 ) F o l l o w - u p ( W k 6 0 ) B a s e l i n e T r e a t m e n t E n d ( W k 4 8 ) F o l l o w - u p ( W k 6 0 ) 0 10 20 30 F r e q u e n c y ( % ) B a s e l i n e T
Slide 14: Key Messages
AB - 729 Key Messages AB - 729 provides robust and comparable HBsAg decline in HBeAg +, HBeAg - , DNA+ and DNA - patients Robust HBsAg declines persist after stopping AB - 729 treatment 26 of 34 patients had HBsAg < 100 IU/mL at some point during the study 5 patients that discontinued both AB - 729
Slide 15: AB-836 Phase 1a/1b Clinical Trial
AB - 836 - 001 Phase 1a/1b Clinical Trial Part 1: Single Ascending Dose In Healthy Subjects Part 2: Multiple Ascending Dose in Healthy Subjects Part 3: Multiple Doses In Chronic Hepatitis B Patients Alternating Cohorts A and B n=8/cohort; 6 active: 2 placebo Cohort A Cohort B ongoing * FE: with Food
Slide 16: AB-836-001 Study: Baseline Characteristics
AB - 836 - 001 Study: Baseline Characteristics 16
Slide 17: Robust HBV DNA Declines with AB-836 50mg, 100mg and 200mg QD
Robust HBV DNA Declines with AB - 836 50 mg, 100mg and 200mg QD 17 Individual HBV DNA responses suggest that any baseline mutations in these cohorts, if present (data pending), did not affect response There were no meaningful changes in HBsAg over 28 days of dosing; HBV RNA data are pending Day 28 H
Slide 18: Safety
AB - 836 Safety 18 Three TEAEs were considered treatment - related (Grade 1 dyspepsia in Cohort G and Grade 3 ALT/Grade 2 AST elevation in 1 Cohort H subject) Two subjects in Cohort G had transient Grade 3 ALT elevations that resolved with continued AB - 836 dosing and were not considered TEAEs Two
Slide 19: IP-10 Levels Remain <2,000 pg/mL in Subjects with Grade 3 ALT in Cohort G
IP - 10 levels remain <2,000 pg /mL in subjects with Grade 3 ALT in Cohort G (100 mg) Patient 1 (Grade 3 ALT) Patient 2 (Grade 3 ALT) 19 The remaining patients with no ALT flares had low IP - 10 levels
Slide 20: IP-10 Levels Spiked >2,000 pg/mL in Patients with Grade 3 and 4 ALT in Cohort H
IP - 10 levels spiked >2,000 pg /mL in patients with Grade 3 and 4 ALT in Cohort H (200 mg) BASELINE DAY 1 DAY 14 DAY 28 EOT DAY 42 DAY 56 0 500 1000 1500 2000 2500 6001-3009 I P - 1 0 ( p g / m L ) Patient 3 (Grade 4 ALT) Patient 4 (Grade 3 ALT) The remaining patients with no ALT flares had low IP
Slide 21: Conclusions AB-836
AB - 836 - 001 Conclusions 21 AB - 836 demonstrated potent inhibition of HBV replication with mean declines in HBV DNA at Day 28 of 3.04 and 3.55 log10 at 100mg QD and 200mg QD, respectively 50mg, 100mg and 200mg QD for 28 days in cHBV patients have been well - tolerated with the safety consideratio
Slide 22: Thank You
Thank You 22